WHAT YOU NEED TO KNOW Last week, CAPA hosted an online panel on the importance of balancing the needs of innovation, access, and affordability when it comes to drug policy. The panel entitled, “Drug Pricing Debate: Why Drug Innovation, Access & Affordability Matter More Than Ever During COVID-19” welcomed discussion with leading experts in the […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, Barron’s highlighted a study that showed how biosimilars of AbbVie’s Humira have saved Europe a bundle.  Biosimilar versions of the antibody product adalimumab have taken some of Humira’s market in Europe and other countries, dropping AbbVie’s foreign sales of Humira by 27% last year. “Biosimilar versions of the antibody product adalimumab […]

Continue Reading

WHAT YOU NEED TO KNOW This month, The Hill published a timely op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse.  Lane penned this piece amidst the COVID-19 pandemic to highlight the need to make sure our drug laws are working to encourage innovation and public-private partnerships for the development of needed drugs while […]

Continue Reading

WHAT YOU NEED TO KNOW According to recent reporting from Reuters, lawmakers are watching closely how Gilead will price their drug remdesivir. Remdesivir, which was developed in part through taxpayer funding, has been touted as a potential treatment for COVID-19. “But it has sued Gilead over patents on two of its widely-used HIV drugs that received federal […]

Continue Reading

WHAT YOU NEED TO KNOW On Friday, writing for The Hill, Matthew Lane, executive director of the Coalition Against Patent Abuse, called on Congress to reexamine the Orphan Drug Act (ODA) and pass an in-case-of-emergency alternative. In his must-read op-ed, Lane examines how the ODA is ill-suited for addressing the global COVID-19 pandemic and highlights the […]

Continue Reading

WHAT YOU NEED TO KNOW This week, the Coalition Against Patent Abuse submitted comments to the FDA/FTC Workshop on Competitive Marketplace for Biosimilars. The FDA and FTC have an important role to play in promoting competition in the pharmaceutical marketplace and encouraging the implementation of sound drug pricing policy that leads to lower prescription drug prices for […]

Continue Reading

WHAT YOU NEED TO KNOW This week, amid public outcry and pressure from groups like CAPA, drugmaker Gilead withdrew its request for the FDA to grant orphan-drug status for remdesivir, an experimental drug that is being tested as a possible treatment for COVID-19. Receiving orphan-status would have given Gilead a seven-year monopoly on a potential cure in […]

Continue Reading

WHAT YOU NEED TO KNOW Last week, the JAMA Network published a must-read study which found that from 2007 to 2018, the net price of brand-name prescription drugs rose by 60 percent. First reported on by Axios, this study emphasizes the growing obstacle everyday Americans face when trying to afford the often lifesaving prescription drugs they need.  To […]

Continue Reading

WHAT YOU NEED TO KNOW U.S. Senator John Cornyn (R-TX) held a roundtable with Texas health professionals to discuss ways to lower prescription drug prices. Senator Cornyn highlighted the bipartisan legislation he introduced alongside Senator Richard Blumenthal (D-CT), the Affordable Prescriptions for Patients Act, which would rein in Big Pharma’s use of patent thickets and promote more […]

Continue Reading

WHAT YOU NEED TO KNOW During a hearing before the Senate Finance Committee, United States Secretary of Health and Human Services Alex Azar highlighted the need for legislation to address Big Pharma’s use of patent thickets to abuse the American patent system. “Just one drug alone the savings from biosimilar market entry would be billions of dollars […]

Continue Reading